Ironwood Pharmaceuticals Reports Third Quarter 2023 Results
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) reported 8% year-over-year growth in LINZESS® (Iinaclotide) EUTRx prescription demand, with U.S. net sales of $279 million, a 7% increase. Positive final data from STARS Nutrition for apraglutide in short bowel syndrome and colon-in-continuity was reported. Phase II study of CNP-104 in primary biliary cholangitis topline data expected in Q3 2024. Maintains Full Year 2023 Guidance.
Positive
8% increase in LINZESS prescription demand indicates growing market demand
Positive final data from STARS Nutrition study supports apraglutide's potential in treating short bowel syndrome and colon-in-continuity
Expected topline data for CNP-104 Phase II study in Q3 2024 shows potential for new treatment in primary biliary cholangitis
Maintaining Full Year 2023 Guidance indicates stability and confidence in future performance
11/09/2023 - 07:00 AM
– LINZESS® (Iinaclotide) EUTRx prescription demand growth increased 8% year-over-year; LINZESS U.S. net sales of $279 million 7% year-over-year –
– Reported positive final data from STARS Nutrition, a Phase II study of apraglutide in short bowel syndrome with intestinal failure (SBS-IF) and colon-in-continuity (CIC) –
– Expects topline data for the Phase II study of CNP-104 in primary biliary cholangitis (PBC) in the third quarter of 2024 –
– Maintains Full Year 2023 Guidance –
BOSTON --(BUSINESS WIRE)--
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its third quarter 2023 results and recent business performance.
“We are proud of the progress we have made across our strategic priorities so far this year, as we believe we have strengthened our position to become the leading GI healthcare company in the industry,” said Tom McCourt, chief executive officer of Ironwood. “Our high conviction in the STARS clinical program was augmented by the positive final data from the STARS Nutrition study, reinforcing our belief in apraglutide’s potential to be a best-in-class GLP-2 analog for the whole spectrum of patients with short bowel syndrome with intestinal failure, including those with colon-in-continuity. In addition, we are encouraged to have seen T-cell immune responses in patients treated with CNP-104 for the potential treatment of primary biliary cholangitis and look forward to the topline results in the third quarter of 2024. Our commitment to developing and advancing innovative GI assets is as strong as it has ever been. We believe the positive momentum across our pipeline programs, combined with the continued strong performance of LINZESS, positions us well for success in our mission to be the leader in GI. We are looking forward to a strong finish to the year and meaningful pipeline catalysts ahead in 2024.”
Third Quarter 2023 Financial Highlights1
(in thousands, except for per share amounts)
Q3 2023
Q3 2022
Total revenues
$
113,739
$
108,637
Total operating expenses
73,716
40,164
GAAP net income
13,950
50,317
GAAP net income attributable to Ironwood Pharmaceuticals, Inc.
15,321
50,317
GAAP net income attributable to Ironwood Pharmaceuticals, Inc. per share – basic
0.10
0.33
GAAP net income attributable to Ironwood Pharmaceuticals, Inc. per share – diluted
0.09
0.28
Adjusted EBITDA
49,079
68,835
Non-GAAP net income
21,802
50,166
Non-GAAP net income per share – basic
0.14
0.33
Non-GAAP net income per share – diluted
0.12
0.28
1.
Refer to the Reconciliation of GAAP Results to Non-GAAP Financial Measures table and to the Reconciliation of GAAP Net Income to Adjusted EBITDA table at the end of this press release. Refer to Non-GAAP Financial Measures for additional information.
Third Quarter 2023 Corporate Highlights
U.S. LINZESS
Prescription Demand : Total LINZESS prescription demand in the third quarter of 2023 was 48 million LINZESS capsules, an 8% increase compared to the third quarter of 2022, per IQVIA.
U.S. Brand CollaborationU.S. net sales are provided to Ironwood by its U.S. partner, AbbVie Inc. (“AbbVie”). LINZESS U.S. net sales were $279.0 million 7% increase compared to $261.1 million
Ironwood and AbbVie share equally in U.S. brand collaboration profits. See the LINZESS U.S. Commercial Collaboration table at the end of the press release.
72% in the third quarter of 2023, compared to 74% in the third quarter of 2022. See the U.S. LINZESS Full Brand Collaboration table below and at the end of this press release.
U.S. brand collaboration, net of commercial and research and development (“R&D”) expenses, was $192.0 million $185.0 million U.S. LINZESS Full Brand Collaboration table below and at the end of this press release.
Collaboration Revenue to Ironwood : Ironwood recorded $110.1 million U.S. , a 5% increase compared to $105.2 million U.S. LINZESS Commercial Collaboration table at the end of the press release.
U.S. LINZESS Full Brand Collaboration
(in thousands, except for percentages)
Three Months Ended
2023
2022
LINZESS U.S. net sales as reported by AbbVie
$278,954
$261,131
AbbVie & Ironwood commercial costs, expenses and other discounts
77,736
68,499
Commercial margin
72%
74%
AbbVie & Ironwood R&D Expenses
9,264
7,620
Total net profit on sales of LINZESS
191,954
185,012
Full brand margin
69%
71%
In October 2023, Ironwood presented new data at the 2023 North American Society for Pediatric Gastroenterology, Hepatology & Nutrition (NASPGHAN) Annual Meeting reinforcing the impact of linaclotide on functional constipation in children and adolescents ages 6-17 years-old. The data demonstrated that linaclotide reduces the need for rescue medications in this patient population and further characterized the efficacy and safety profile of linaclotide as the only FDA-approved prescription therapy for this population. Additional details can be found here .
Pipeline Updates
Apraglutide
Ironwood is advancing apraglutide, a next-generation, synthetic glucagon-like peptide-2 (“GLP-2”) analog for short bowel syndrome with intestinal failure (“SBS-IF”), a severe malabsorptive condition. Ironwood believes apraglutide has the potential to be the new standard of care for the treatment of SBS-IF based on its potency and pharmacological properties. Ironwood is conducting a Phase III clinical trial, STARS, designed to evaluate clinical benefit for both SBS-IF stoma and colon-in-continuity (“CIC”) patients with unique convenience of weekly dosing. Topline results are expected in March of 2024.
In October 2023, Ironwood presented positive final data from the company’s Phase II STARS Nutrition program during United European Gastroenterology (UEG) Week. This multicenter, open-label study of nine patients was designed to evaluate the safety, pharmacokinetics, and efficacy of apraglutide on intestinal absorption in adult patients who have SBS-IF and CIC. Additional details can be found here .
Ironwood is also conducting a Phase II proof-of-concept clinical trial, STARGAZE, to evaluate apraglutide in patients with steroid-refractory gastrointestinal acute Graft versus Host Disease (aGvHD), a life-threatening condition that occurs when immune cells from the donor attack a recipient’s healthy cells after an allogeneic hematopoietic stem cell transplant. Enrollment is completed and data is expected for the STARGAZE Phase II clinical trial in the first quarter of 2024.
CNP-104
Ironwood has a collaboration and license option agreement with COUR Pharmaceuticals Development Company, Inc. (“COUR”). This agreement grants Ironwood an option to acquire an exclusive license to research, develop, manufacture and commercialize, in the U.S. , products containing CNP-104 (“CNP-104”), a tolerizing immune modifying nanoparticle, for the treatment of primary biliary cholangitis (“PBC”), a rare autoimmune disease targeting the liver. If successful, CNP-104 has the potential to be the first approved PBC disease modifying therapy.
COUR is currently conducting a clinical study for CNP-104 evaluating the safety, tolerability, pharmacodynamic effects and efficacy of CNP-104 in PBC patients, with topline data expected in the third quarter of 2024.
IW-3300
Ironwood is currently advancing IW-3300, a guanylate cyclase-C agonist being developed for the potential treatment of visceral pain conditions, such as interstitial cystitis / bladder pain syndrome (“IC/BPS”) and endometriosis. Ironwood is continuing the Phase II proof of concept study in IC/BPS.
Third Quarter 2023 Financial Results
Total Revenues. Total revenues in the third quarter of 2023 were $113.7 million $108.6 million
– Total revenues in the third quarter of 2023 consisted of $110.1 million U.S. and $3.6 million $105.2 million U.S. and $3.4 million
Operating Expenses . Operating expenses in the third quarter of 2023 were $73.7 million $40.2 million
– Operating expenses in the third quarter of 2023 consisted of $36.0 million $33.0 million $4.7 million $28.6 million $11.6 million
Interest Expense and Other Financing Costs. Interest expense was $9.8 million $9.2 million $0.6 million $1.5 million $1.1 million $0.4 million
Interest and Investment Income. Interest and investment income was $1.7 million $2.8 million
Gain on Derivatives. Ironwood recorded a gain on derivatives of $0.2 million
Income Tax Expense. Ironwood recorded $18.0 million $19.6 million
GAAP Net Income Attributable to Ironwood. GAAP net income was $15.3 million $0.10 $0.09 $50.3 million $0.33 $0.28
Non-GAAP Net Income. Non-GAAP net income was $21.8 million $0.14 $0.12 $50.2 million $0.33 $0.28
– Non-GAAP net income excludes the impact of mark-to-market adjustments on the derivatives related to Ironwood’s 2022 Convertible Notes, amortization of acquired intangible assets, restructuring expenses and acquisition-related costs, all net of tax effect. See Non-GAAP Financial Measures below.
Adjusted EBITDA . Adjusted EBITDA was $49.1 million $68.8 million
– Adjusted EBITDA is calculated by subtracting mark-to-market adjustments on derivatives related to Ironwood’s 2022 Convertible Notes, restructuring expenses, acquisition-related costs, net interest expense, income taxes, depreciation and amortization, and acquisition-related costs, from GAAP net income. See Non-GAAP Financial Measures below.
Cash Flow Highlights. Ironwood ended the third quarter of 2023 with $110.2 million $656.2 million
– In September 2023, Ironwood repaid $75.0 million $325.0 million
– Ironwood generated approximately $32.5 million $69.1 million
Ironwood 2023 Financial Guidance. In 2023, Ironwood continues to expect:
2023 Guidance
U.S. LINZESS Net Sales Growth
6% to 8%
Total Revenue
$435 $450 million
Adjusted EBITDA1
~ ($900) million 2
Includes a one-time charge of approximately $1.1
1 Adjusted EBITDA is calculated by subtracting mark-to-market adjustments on derivatives related to Ironwood’s 2022 Convertible Notes, restructuring expenses, net interest expense, income taxes, depreciation and amortization, and acquisition-related costs from GAAP net income.
2 2023 adjusted EBITDA guidance includes a one-time charge of approximately $1.1 billion
Non-GAAP Financial Measures
Ironwood presents non-GAAP net income and non-GAAP net income per share to exclude the impact, net of tax effects, of net gains and losses on derivatives related to Ironwood’s 2022 Convertible Notes that are required to be marked-to-market, amortization of acquired intangible assets, restructuring expenses, and acquisition-related costs. Non-GAAP adjustments are further detailed below:
The gains and losses on the derivatives related to Ironwood’s 2022 Convertible Notes were highly variable, difficult to predict and of a size that could have a substantial impact on the company’s reported results of operations in any given period.
Amortization of acquired intangible assets are non-cash expenses arising in connection with the acquisition of VectivBio and are considered to be non-recurring.
Restructuring expenses are considered to be a non-recurring event as they are associated with distinct operational decisions. Included in restructuring expenses are costs associated with exit and disposal activities.
Acquisition-related costs in connection with the acquisition of VectivBio are considered to be non-recurring and include direct and incremental costs associated with the acquisition and integration of VectivBio to the extent such costs were not classified as capitalizable transaction costs attributed to the cost of net assets acquired through acquisition accounting.
Ironwood also presents adjusted EBITDA, a non-GAAP measure, as well as guidance on adjusted EBITDA. Adjusted EBITDA is calculated by subtracting mark-to-market adjustments on derivatives related to Ironwood’s 2022 Convertible Notes, restructuring expenses, net interest expense, income taxes, depreciation and amortization, and acquisition-related costs from GAAP net income. The adjustments are made on a similar basis as described above related to non-GAAP net income, as applicable.
Management believes this non-GAAP information is useful for investors, taken in conjunction with Ironwood’s GAAP financial statements, because it provides greater transparency and period-over-period comparability with respect to Ironwood’s operating performance. These measures are also used by management to assess the performance of the business. Investors should consider these non-GAAP measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP. In addition, these non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies. For a reconciliation of non-GAAP net income and non-GAAP net income per share to GAAP net income and GAAP net income per share, respectively, and for a reconciliation of adjusted EBITDA to GAAP net income, please refer to the tables at the end of this press release.
Ironwood does not provide guidance on GAAP net income or a reconciliation of expected adjusted EBITDA to expected GAAP net income because, without unreasonable efforts, it is unable to predict with reasonable certainty the non-GAAP adjustments used to calculate adjusted EBITDA. These adjustments are uncertain, depend on various factors and could have a material impact on GAAP net income for the guidance period.
Conference Call Information
Ironwood will host a conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 9, 2023 to discuss its third quarter 2023 results and recent business activities. Individuals interested in participating in the call should dial (888) 330-2384 (U.S. and Canada ) or (240) 789-2701 (international) using conference ID number and event passcode 4671230. To access the webcast, please visit the Investors section of Ironwood’s website at www.ironwoodpharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required. The call will be available for replay via telephone starting at approximately 11:30 a.m. Eastern Time on November 9, 2023, running through 11:59 p.m. Eastern Time on November 23, 2023. To listen to the replay, dial (800) 770-2030 (U.S. and Canada ) or (647) 362-9199 (international) using conference ID number 4671230. The archived webcast will be available on Ironwood’s website for 14 days beginning approximately one hour after the call has completed.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (Nasdaq: IRWD), an S&P SmallCap 600® company, is a leading global gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and redefine the standard of care for GI patients. We are pioneers in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). LINZESS is also approved for the treatment of functional constipation in pediatric patients ages 6-17 years-old. Ironwood is also advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog being developed for rare gastrointestinal diseases, including short bowel syndrome with intestinal failure (SBS-IF) as well as several earlier stage assets. Building upon our history of GI innovation, we keep patients at the heart of our R&D and commercialization efforts to reduce the burden of GI diseases and address significant unmet needs.
Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts , and has additional operations in Basel, Switzerland .
We routinely post information that may be important to investors on our website at www.ironwoodpharma.com . In addition, follow us on X and on LinkedIn .
About LINZESS (Linaclotide)
LINZESS® is the #1 prescribed brand in the U.S. for the treatment of adult patients with irritable bowel syndrome with constipation (“IBS-C”) or chronic idiopathic constipation (“CIC”), based on IQVIA data. LINZESS is a once-daily capsule that helps relieve the abdominal pain, constipation, and overall abdominal symptoms of bloating, discomfort and pain associated with IBS-C, as well as the constipation, infrequent stools, hard stools, straining, and incomplete evacuation associated with CIC. LINZESS relieves constipation in children and adolescents aged 6 to 17 years with functional constipation. The recommended dose is 290 mcg for IBS-C patients and 145 mcg for CIC patients, with a 72 mcg dose approved for use in CIC depending on individual patient presentation or tolerability. In children with functional constipation aged 6 to 17 years, the recommended dose is 72 mcg.
LINZESS is not a laxative; it is the first medicine approved by the FDA in a class called GC-C agonists. LINZESS contains a peptide called linaclotide that activates the GC-C receptor in the intestine. Activation of GC-C is thought to result in increased intestinal fluid secretion and accelerated transit and a decrease in the activity of pain-sensing nerves in the intestine. The clinical relevance of the effect on pain fibers, which is based on nonclinical studies, has not been established.
In the United States , Ironwood and AbbVie co-develop and co-commercialize LINZESS for the treatment of adults with IBS-C or CIC. In Europe , AbbVie markets linaclotide under the brand name CONSTELLA® for the treatment of adults with moderate to severe IBS-C. In Japan , Ironwood's partner, Astellas, markets linaclotide under the brand name LINZESS for the treatment of adults with IBS-C or CIC. Ironwood also has partnered with AstraZeneca for development and commercialization of LINZESS in China , and with AbbVie for development and commercialization of linaclotide in all other territories worldwide.
LINZESS Important Safety Information
INDICATIONS AND USAGE
LINZESS® (linaclotide) is indicated for the treatment of both irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) in adults and functional constipation (FC) in children and adolescents 6 to 17 years of age. It is not known if LINZESS is safe and effective in children with FC less than 6 years of age or in children with IBS-C less than 18 years of age.
IMPORTANT SAFETY INFORMATION
WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS LESS THAN 2 YEARS OF AGE
LINZESS is contraindicated in patients less than 2 years of age. In nonclinical studies in neonatal mice, administration of a single, clinically relevant adult oral dose of linaclotide caused deaths due to dehydration.
Contraindications
LINZESS is contraindicated in patients less than 2 years of age due to the risk of serious dehydration.
LINZESS is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.
Warnings and Precautions
LINZESS is contraindicated in patients less than 2 years of age. In neonatal mice, linaclotide increased fluid secretion as a consequence of age-dependent elevated guanylate cyclase (GC-C) agonism, which was associated with increased mortality within the first 24 hours due to dehydration. There was no age dependent trend in GC-C intestinal expression in a clinical study of children 2 to less than 18 years of age; however, there are insufficient data available on GC-C intestinal expression in children less than 2 years of age to assess the risk of developing diarrhea and its potentially serious consequences in these patients.
Diarrhea
In adults, diarrhea was the most common adverse reaction in LINZESS-treated patients in the pooled IBS-C and CIC double-blind placebo-controlled trials. The incidence of diarrhea was similar in the IBS-C and CIC populations. Severe diarrhea was reported in 2% of 145 mcg and 290 mcg LINZESS-treated patients and in <1% of 72 mcg LINZESS-treated CIC patients.
In children and adolescents 6 to 17 years of age, diarrhea was the most common adverse reaction in 72 mcg LINZESS-treated patients in the FC double-blind placebo-controlled trial. Severe diarrhea was reported in <1% of 72 mcg LINZESS treated patients. If severe diarrhea occurs, dosing should be suspended and the patient rehydrated.
Common Adverse Reactions (incidence ≥2% and greater than placebo)
In IBS-C or CIC adult patients: diarrhea, abdominal pain, flatulence, and abdominal distension.
In FC pediatric patients: diarrhea.
Please see full Prescribing Information including Boxed Warning:
https://www.rxabbvie.com/pdf/linzess_pi.pdf
LINZESS® and CONSTELLA® are registered trademarks of Ironwood Pharmaceuticals, Inc. Any other trademarks referred to in this press release are the property of their respective owners. All rights reserved.
Forward-Looking Statements
This press release contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about Ironwood’s ability to execute on its mission; Ironwood’s strategy, business, financial position and operations; Ironwood’s ability to drive growth and profitability; the demand, development, commercial availability and commercial potential of linaclotide, including pursuing highly differentiated GI assets to add to our portfolio, and the drivers, timing, impact and results thereof; the potential indications for, and benefits of, linaclotide; our financial performance and results, and guidance and expectations related thereto; LINZESS prescription demand growth, LINZESS U.S. net sales growth, total revenue and adjusted EBITDA in 2023; our ability to develop apraglutide and the expected timing of receiving data from the apraglutide clinical trials; the potential of apraglutide to become the standard of care for patients with SBS-IF; the potential of CNP-104 to be the first PBC disease modifying therapy and the expected timing of receiving topline data from the clinical study for CNP-104 in PBC patients; and our plan to advance IW-3300 including the timing and results thereof. These forward-looking statements speak only as of the date of this press release, and Ironwood undertakes no obligation to update these forward-looking statements. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include those related to the effectiveness of development and commercialization efforts by us and our partners; preclinical and clinical development, manufacturing and formulation development of linaclotide, apraglutide, CNP-104, IW-3300, and our product candidates; the risk that clinical programs and studies, including for the linaclotide pediatric program, apraglutide, IW-3300 and CNP-104, may not progress or develop as anticipated, including that studies are delayed or discontinued for any reason, such as safety, tolerability, enrollment, manufacturing, economic or other reasons; the risk that findings from our completed nonclinical and clinical studies may not be replicated in later studies; the risk that peripheral T-cell immune responses evidenced in patients treated with CNP-104 may neither support the mechanistic rationale for CNP-104 nor be predictive of the topline data from the clinical study for CNP-104 in PBC patients since the clinical relevance of such T-cell immune response has not been adequately established; the risk that we or our partners are unable to obtain, maintain or manufacture sufficient LINZESS or our product candidates, or otherwise experience difficulties with respect to supply or manufacturing; the efficacy, safety and tolerability of linaclotide and our product candidates; the risk that the commercial and therapeutic opportunities for LINZESS or our product candidates are not as we expect; decisions by regulatory and judicial authorities; the risk we may never get additional patent protection for linaclotide and other product candidates, that patents for linaclotide or other products may not provide adequate protection from competition, or that we are not able to successfully protect such patents; the risk that we are unable to manage our expenses or cash use, or are unable to commercialize our products as expected; the risk that the development of any of our linaclotide pediatric programs, apraglutide, CNP-104 and/or IW-3300 are not successful or that any of our product candidates is not successfully commercialized; outcomes in legal proceedings to protect or enforce the patents relating to our products and product candidates, including abbreviated new drug application litigation; the risk that financial and operating results may differ from our projections; developments in the intellectual property landscape; challenges from and rights of competitors or potential competitors; the risk that our planned investments do not have the anticipated effect on our company revenues; developments in accounting guidance or practice; Ironwood’s or AbbVie’s accounting practices, including reporting and settlement practices as between Ironwood and AbbVie; the risk that we are unable to manage our expenses or cash use, or are unable to commercialize our products as expected; the impact of the COVID-19 pandemic; and the risks listed under the heading “Risk Factors” and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2022, in our Quarterly Report on Form 10-Q for the second quarter ended June 30, 2023, and in our subsequent Securities and Exchange Commission filings.
Condensed Consolidated Balance Sheets
(In thousands)
(unaudited)
September 30,
December 31,
Assets
Cash and cash equivalents
$
110,164
$
656,203
Accounts receivable, net
124,546
115,458
Prepaid expenses and other current assets
18,112
7,715
Restricted cash
788
1,250
Total current assets
253,610
780,626
Restricted cash, net of current portion
510
485
Accounts receivable, net of current portion
-
14,589
Property and equipment, net
5,630
6,288
Operating lease right-of-use assets
12,956
14,023
Intangible assets, net
3,889
-
Deferred tax assets
243,645
283,661
Other assets
3,823
847
Total assets
$
524,063
$
1,100,519
Liabilities and Stockholders’ Equity
Accounts payable
$
4,698
$
483
Accrued research and development costs
10,735
5,258
Accrued expenses and other current liabilities
62, 714
16,700
Current portion of operating lease liabilities
3,111
3,065
Current portion on convertible senior notes
199,321
-
Note hedge warrants
-
19
Total current liabilities
280,579
25,525
Operating lease liabilities, net of current portion
15,074
16,599
Convertible senior notes, net of current portion
198,141
396,251
Revolving credit facility
325,000
-
Other liabilities
30,948
9,766
Total stockholders’ equity (deficit)
(325,679
)
652,378
Total liabilities and stockholders’ equity (deficit)
$
524,063
$
1,100,519
Condensed Consolidated Statements of Income
(In thousands, except per share amounts)
(unaudited)
Three Months Ended
September 30,
Nine Months Ended
September 30,
2023
2022
2023
2022
Revenues
Collaborative arrangements revenue
$
113,739
$
108,637
$
325,182
$
303,397
Total revenues
113,739
108,637
325,182
303,397
Operating expenses:
Research and development
32,985
11,545
80,409
33,819
Selling, general and administrative
36,046
28,619
119,647
87,604
Restructuring expenses
4,685
-
17,696
-
Acquired in-process research and development
-
-
1,090,449
-
Total operating expenses
73,716
40,164
1,308,201
121,423
Income (loss) from operations
40,023
68,473
(983,019
)
181,974
Other income (expense):
Interest expense and other financing costs
(9,839
)
(1,524
)
(13,206
)
(6,072
)
Interest and investment income
1,748
2,807
17,777
4,055
Gain on derivatives
-
151
19
200
Other income (expense), net
(8,091
)
1,434
4,590
(1,817
)
Income (loss) before income taxes
31,932
69,907
(978,429
)
180,157
Income tax expense
(17,982
)
(19,590
)
(51,385
)
(53,959
)
GAAP net income (loss)
13,950
50,317
(1,029,814
)
126,198
Less: GAAP net income (loss) attributable to noncontrolling interests
(1,371
)
-
(28,662
)
-
GAAP net income (loss) attributable to Ironwood Pharmaceuticals, Inc.
$
15,321
$
50,317
$
(1,001,152
)
$
126,198
GAAP net income (loss) attributable to Ironwood Pharmaceuticals, Inc. per share—basic
$0.10
$0.33
($6.45
)
$0.82
GAAP net income (loss) attributable to Ironwood Pharmaceuticals, Inc. per share—diluted
$0.09
$0.28
($6.45
)
$0.69
Reconciliation of GAAP Results to Non-GAAP Financial Measures
(In thousands, except per share amounts) (unaudited)
A reconciliation between net income (loss) on a GAAP basis and on a non-GAAP basis is as follows:
Three Months Ended
Nine Months Ended
2023
2022
2023
2022
GAAP net income (loss)1
$
13,950
$
50,317
$
(1,029,814
)
$
126,198
Adjustments:
Mark-to-market adjustments on the derivatives related to convertible notes, net
-
(151
)
(19
)
(200
)
Amortization of acquired intangible assets
207
-
211
-
Restructuring expenses
4,685
-
17,696
-
Acquisition-related costs
3,864
-
39,545
-
Tax effect of adjustments
(904
)
-
(1,447
)
-
Non-GAAP net income (loss)1
$
21,802
$
50,166
$
(973,828
)
$
125,998
A reconciliation between basic net income (loss) per share on a GAAP basis and on a non-GAAP basis is as follows:
Three Months Ended
September 30,
Nine Months Ended
September 30,
2023
2022
2023
2022
GAAP net income (loss) attributable to Ironwood Pharmaceuticals, Inc. per share – basic
$
0.10
$
0.33
$
(6.45
)
$
0.82
Plus: GAAP net income (loss) attributable to noncontrolling interests – basic
(0.01
)
-
(0.18
)
-
Adjustments to GAAP net income (loss) per share (as detailed above)
0.05
-
0.36
-
Non-GAAP net income (loss) per share – basic
$
0.14
$
0.33
$
(6.27
)
$
0.82
Weighted average number of common shares used to calculate net income (loss) per share — basic
155,886
153,066
155,240
154,713
A reconciliation between diluted net income (loss) per share on a GAAP basis and on a non-GAAP basis is as follows:
Three Months Ended
September 30,
Nine Months Ended
2023
2022
2023
2022
GAAP net income (loss) attributable to Ironwood Pharmaceuticals, Inc. per share – diluted
$
0.09
$
0.28
$
(6.45
)
$
0.69
Plus: GAAP net income (loss) attributable to noncontrolling interests – diluted
$
(0.01
)
-
$
(0.18
)
-
Adjustments to GAAP net income (loss) per share (as detailed above)
0.04
-
0.36
-
Non-GAAP net income (loss) per share – diluted
$
0.12
$
0.28
$
(6.27
)
$
0.69
Weighted average number of common shares used to calculate net income (loss) per share — diluted
186,891
184,465
155,240
186,504
__________________
1 GAAP and non-GAAP net loss for nine months ended September 30, 2023 include a one-time charge of approximately $1.1 billion
Reconciliation of GAAP Net Income to Adjusted EBITDA
(In thousands)
(unaudited)
A reconciliation of GAAP net income (loss) to adjusted EBITDA:
Three Months Ended
September 30,
Nine Months Ended
September 30,
2023
2022
2023
2022
GAAP net income (loss)1
$
13,950
$
50,317
$
(1,029,814
)
$
126,198
Adjustments:
Mark-to-market adjustments on the derivatives related to convertible notes, net
-
(151
)
(19
)
(200
)
Restructuring expenses
4,685
-
17,696
-
Interest expense
9,839
1,524
13,206
6,072
Interest and investment income
(1,748
)
(2,807
)
(17,777
)
(4,055
)
Income tax expense
17,982
19,590
51,385
53,959
Depreciation and amortization
507
362
1,063
1,078
Acquisition-related costs
3,864
-
39,545
-
Adjusted EBITDA1
$
49,079
$
68,835
$
(924,715
)
$
183,052
__________________
1 GAAP net loss and adjusted EBITDA for nine months ended September 30, 2023 includes a one-time charge of approximately $1.1 billion
U.S. LINZESS Commercial Collaboration1
Revenue/Expense Calculation
(In thousands)
(unaudited)
Three Months Ended
September 30,
Nine Months Ended
September 30,
2023
2022
2023
2022
LINZESS U.S. net sales as reported by AbbVie2
$
278,954
$
261,131
$
798,854
$
741,816
AbbVie & Ironwood commercial costs, expenses and other discounts3
77,736
68,499
223,142
205,878
Commercial profit on sales of LINZESS
$
201,218
$
192,632
$
575,712
$
535,938
Commercial Margin4
72
%
74
%
72
%
72
%
Ironwood’s share of net profit
100,609
96,316
287,856
267,969
Reimbursement for Ironwood’s commercial expenses
9,480
8,908
28,615
26,026
Ironwood’s collaborative arrangement revenue
$
110,089
$
105,224
$
316,471
$
293,995
__________________
1 Ironwood collaborates with AbbVie on the development and commercialization of linaclotide in North America . Under the terms of the collaboration agreement, Ironwood receives 50% of the net profits and bears 50% of the net losses from the commercial sale of LINZESS in the U.S. The purpose of this table is to present calculations of Ironwood’s share of net profit (loss) generated from the sales of LINZESS in the U.S. and Ironwood’s collaboration revenue/expense; however, the table does not present the research and development expenses related to LINZESS in the U.S. that are shared equally between the parties under the collaboration agreement. Please refer to the table at the end of this press release for net profit for the U.S. LINZESS brand collaboration with AbbVie.
2 LINZESS net sales are recognized using AbbVie’s revenue recognition accounting policies and reporting conventions. As a result, certain rebates and discounts are classified as LINZESS U.S. commercial costs, expenses and other discounts within Ironwood’s calculation of collaborative arrangements revenue.
3 Includes certain discounts recognized and cost of goods sold incurred by AbbVie; also includes commercial costs incurred by AbbVie and Ironwood that are attributable to the cost-sharing arrangement between the parties.
4 Commercial margin is defined as commercial profit on sales of LINZESS as a percent of total LINZESS U.S. net sales.
US LINZESS Full Brand Collaboration1
Revenue/Expense Calculation
(In thousands)
(unaudited)
Three Months Ended
September 30,
Nine Months Ended
September 30,
2023
2022
2023
2022
LINZESS U.S. net sales as reported by AbbVie2
$
278,954
$
261,131
$
798,854
$
741,816
AbbVie & Ironwood commercial costs, expenses and other discounts3
77,736
68,499
223,142
205,878
AbbVie & Ironwood R&D Expenses4
9,264
7,620
28,270
24,000
Total net profit on sales of LINZESS
$
191,954
$
185,012
$
547,442
$
511,938
__________________
1 Ironwood collaborates with AbbVie on the development and commercialization of linaclotide in North America . Under the terms of the collaboration agreement, Ironwood receives 50% of the net profits and bears 50% of the net losses from the commercial sale of LINZESS in the U.S. The purpose of this table is to present calculations of the total net profit (loss) generated from the sales of LINZESS in the U.S. , including the commercial costs and expenses and the research and development expenses related to LINZESS in the U.S. that are shared equally between the parties under the collaboration agreement.
2 LINZESS net sales are recognized using AbbVie’s revenue recognition accounting policies and reporting conventions. As a result, certain rebates and discounts are classified as LINZESS U.S. commercial costs, expenses and other discounts within Ironwood’s calculation of collaborative arrangements revenue.
3 Includes certain discounts recognized and cost of goods sold incurred by AbbVie; also includes commercial costs incurred by AbbVie and Ironwood that are attributable to the cost-sharing arrangement between the parties.
4 R&D expenses related to LINZESS in the U.S. are shared equally between Ironwood and AbbVie under the collaboration agreement.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231109546088/en/
Investors:
gmartini@ironwoodpharma.com
Matt Roache, 617-621-8395
mroache@ironwoodpharma.com
Media:
bcalitri@ironwoodpharma.com
Source: Ironwood Pharmaceuticals, Inc.
What was the year-over-year increase in LINZESS prescription demand?
LINZESS prescription demand grew by 8% year-over-year.
What was the increase in LINZESS U.S. net sales?
LINZESS U.S. net sales saw a 7% increase, reaching $279 million.
What was the outcome of the STARS Nutrition study for apraglutide?
Positive final data from the STARS Nutrition study was reported, reinforcing apraglutide's potential in treating short bowel syndrome and colon-in-continuity.
When is the topline data for the Phase II study of CNP-104 in primary biliary cholangitis expected?
Topline data for the Phase II study of CNP-104 in primary biliary cholangitis is expected in the third quarter of 2024.
What guidance did Ironwood Pharmaceuticals maintain for Full Year 2023?
Ironwood Pharmaceuticals maintained Full Year 2023 Guidance, indicating stability and confidence in future performance.
